Atreca, Inc. (BCEL)
- Previous Close
0.0850 - Open
0.0800 - Bid 0.1830 x 1000
- Ask 0.1900 x 900
- Day's Range
0.0800 - 0.0918 - 52 Week Range
0.0520 - 1.2640 - Volume
20,189 - Avg. Volume
934,217 - Market Cap (intraday)
3.39M - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5000 - Earnings Date Apr 26, 2024 - Apr 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.50
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.
www.atreca.comRecent News: BCEL
Performance Overview: BCEL
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCEL
Valuation Measures
Market Cap
3.39M
Enterprise Value
-16.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.32
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.24
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.20%
Return on Equity (ttm)
-182.70%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-97.76M
Diluted EPS (ttm)
-2.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
21.39M
Total Debt/Equity (mrq)
11.91%
Levered Free Cash Flow (ttm)
-25.99M